Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
2.
Cardiovasc Drugs Ther ; 24(4): 311-7, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20549322

ABSTRACT

Coronary artery disease is the major cause of death in the western world. The formation and rapid progression of atheromatous plaques can lead to serious cardiovascular events in patients with atherosclerosis. The better understanding, in recent years, of the mechanisms leading to atheromatous plaque growth and disruption and the availability of powerful HMG CoA-reductase inhibitors (statins) has permitted the consideration of plaque regression as a realistic therapeutic goal. This article reviews the existing evidence underpinning current therapeutic strategies aimed at achieving atherosclerotic plaque regression. In this review we also discuss imaging modalities for the assessment of plaque regression, predictors of regression and whether plaque regression is associated with a survival benefit.


Subject(s)
Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Lipoproteins, LDL/blood , Plaque, Atherosclerotic , Acute Coronary Syndrome/etiology , Acute Coronary Syndrome/physiopathology , Acute Coronary Syndrome/prevention & control , Arteries/diagnostic imaging , Arteries/pathology , Atherosclerosis/complications , Atherosclerosis/drug therapy , Atherosclerosis/physiopathology , Clinical Trials as Topic , Coronary Artery Disease/complications , Coronary Artery Disease/drug therapy , Coronary Artery Disease/physiopathology , Disease Progression , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Magnetic Resonance Imaging , Plaque, Atherosclerotic/diagnostic imaging , Plaque, Atherosclerotic/metabolism , Plaque, Atherosclerotic/pathology , Treatment Outcome , Ultrasonography, Interventional
SELECTION OF CITATIONS
SEARCH DETAIL
...